Pharmacogenetics of proton pump inhibitors
Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of acti...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
M. V. Leonova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Медицинский совет - Remedium Group LLC, 2019, (2015), 17, Seite 96-103 |
|---|---|
| Übergeordnetes Werk: |
year:2015 ; number:17 ; pages:96-103 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.21518/2079-701X-2015-17-96-103 |
|---|
| Katalog-ID: |
DOAJ033457409 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ033457409 | ||
| 003 | DE-627 | ||
| 005 | 20230505014245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2015 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2015-17-96-103 |2 doi | |
| 035 | |a (DE-627)DOAJ033457409 | ||
| 035 | |a (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a M. V. Leonova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetics of proton pump inhibitors |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. | ||
| 650 | 4 | |a ингибиторы протонной помпы | |
| 650 | 4 | |a эрадикационная терапия | |
| 650 | 4 | |a proton pump inhibitors | |
| 650 | 4 | |a eradication therapy | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2015), 17, Seite 96-103 |w (DE-627)1760607460 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2015 |g number:17 |g pages:96-103 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2015-17-96-103 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/433 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2015 |e 17 |h 96-103 | ||
| author_variant |
m v l mvl |
|---|---|
| matchkey_str |
article:26585790:2015----::hraoeeisfrtnu |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.21518/2079-701X-2015-17-96-103 doi (DE-627)DOAJ033457409 (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe DE-627 ger DE-627 rakwb rus M. V. Leonova verfasserin aut Pharmacogenetics of proton pump inhibitors 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy Medicine R In Медицинский совет Remedium Group LLC, 2019 (2015), 17, Seite 96-103 (DE-627)1760607460 26585790 nnns year:2015 number:17 pages:96-103 https://doi.org/10.21518/2079-701X-2015-17-96-103 kostenfrei https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe kostenfrei https://www.med-sovet.pro/jour/article/view/433 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2015 17 96-103 |
| spelling |
10.21518/2079-701X-2015-17-96-103 doi (DE-627)DOAJ033457409 (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe DE-627 ger DE-627 rakwb rus M. V. Leonova verfasserin aut Pharmacogenetics of proton pump inhibitors 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy Medicine R In Медицинский совет Remedium Group LLC, 2019 (2015), 17, Seite 96-103 (DE-627)1760607460 26585790 nnns year:2015 number:17 pages:96-103 https://doi.org/10.21518/2079-701X-2015-17-96-103 kostenfrei https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe kostenfrei https://www.med-sovet.pro/jour/article/view/433 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2015 17 96-103 |
| allfields_unstemmed |
10.21518/2079-701X-2015-17-96-103 doi (DE-627)DOAJ033457409 (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe DE-627 ger DE-627 rakwb rus M. V. Leonova verfasserin aut Pharmacogenetics of proton pump inhibitors 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy Medicine R In Медицинский совет Remedium Group LLC, 2019 (2015), 17, Seite 96-103 (DE-627)1760607460 26585790 nnns year:2015 number:17 pages:96-103 https://doi.org/10.21518/2079-701X-2015-17-96-103 kostenfrei https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe kostenfrei https://www.med-sovet.pro/jour/article/view/433 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2015 17 96-103 |
| allfieldsGer |
10.21518/2079-701X-2015-17-96-103 doi (DE-627)DOAJ033457409 (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe DE-627 ger DE-627 rakwb rus M. V. Leonova verfasserin aut Pharmacogenetics of proton pump inhibitors 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy Medicine R In Медицинский совет Remedium Group LLC, 2019 (2015), 17, Seite 96-103 (DE-627)1760607460 26585790 nnns year:2015 number:17 pages:96-103 https://doi.org/10.21518/2079-701X-2015-17-96-103 kostenfrei https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe kostenfrei https://www.med-sovet.pro/jour/article/view/433 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2015 17 96-103 |
| allfieldsSound |
10.21518/2079-701X-2015-17-96-103 doi (DE-627)DOAJ033457409 (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe DE-627 ger DE-627 rakwb rus M. V. Leonova verfasserin aut Pharmacogenetics of proton pump inhibitors 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy Medicine R In Медицинский совет Remedium Group LLC, 2019 (2015), 17, Seite 96-103 (DE-627)1760607460 26585790 nnns year:2015 number:17 pages:96-103 https://doi.org/10.21518/2079-701X-2015-17-96-103 kostenfrei https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe kostenfrei https://www.med-sovet.pro/jour/article/view/433 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2015 17 96-103 |
| language |
Russian |
| source |
In Медицинский совет (2015), 17, Seite 96-103 year:2015 number:17 pages:96-103 |
| sourceStr |
In Медицинский совет (2015), 17, Seite 96-103 year:2015 number:17 pages:96-103 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Медицинский совет |
| authorswithroles_txt_mv |
M. V. Leonova @@aut@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
1760607460 |
| id |
DOAJ033457409 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ033457409</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505014245.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2015 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21518/2079-701X-2015-17-96-103</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ033457409</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Leonova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacogenetics of proton pump inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ингибиторы протонной помпы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">эрадикационная терапия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">proton pump inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">eradication therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинский совет</subfield><subfield code="d">Remedium Group LLC, 2019</subfield><subfield code="g">(2015), 17, Seite 96-103</subfield><subfield code="w">(DE-627)1760607460</subfield><subfield code="x">26585790</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2015</subfield><subfield code="g">number:17</subfield><subfield code="g">pages:96-103</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21518/2079-701X-2015-17-96-103</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.med-sovet.pro/jour/article/view/433</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-701X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5790</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2015</subfield><subfield code="e">17</subfield><subfield code="h">96-103</subfield></datafield></record></collection>
|
| author |
M. V. Leonova |
| spellingShingle |
M. V. Leonova misc ингибиторы протонной помпы misc эрадикационная терапия misc proton pump inhibitors misc eradication therapy misc Medicine misc R Pharmacogenetics of proton pump inhibitors |
| authorStr |
M. V. Leonova |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760607460 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
26585790 |
| topic_title |
Pharmacogenetics of proton pump inhibitors ингибиторы протонной помпы эрадикационная терапия proton pump inhibitors eradication therapy |
| topic |
misc ингибиторы протонной помпы misc эрадикационная терапия misc proton pump inhibitors misc eradication therapy misc Medicine misc R |
| topic_unstemmed |
misc ингибиторы протонной помпы misc эрадикационная терапия misc proton pump inhibitors misc eradication therapy misc Medicine misc R |
| topic_browse |
misc ингибиторы протонной помпы misc эрадикационная терапия misc proton pump inhibitors misc eradication therapy misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Медицинский совет |
| hierarchy_parent_id |
1760607460 |
| hierarchy_top_title |
Медицинский совет |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760607460 |
| title |
Pharmacogenetics of proton pump inhibitors |
| ctrlnum |
(DE-627)DOAJ033457409 (DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe |
| title_full |
Pharmacogenetics of proton pump inhibitors |
| author_sort |
M. V. Leonova |
| journal |
Медицинский совет |
| journalStr |
Медицинский совет |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
96 |
| author_browse |
M. V. Leonova |
| format_se |
Elektronische Aufsätze |
| author-letter |
M. V. Leonova |
| doi_str_mv |
10.21518/2079-701X-2015-17-96-103 |
| title_sort |
pharmacogenetics of proton pump inhibitors |
| title_auth |
Pharmacogenetics of proton pump inhibitors |
| abstract |
Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. |
| abstractGer |
Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. |
| abstract_unstemmed |
Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
17 |
| title_short |
Pharmacogenetics of proton pump inhibitors |
| url |
https://doi.org/10.21518/2079-701X-2015-17-96-103 https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe https://www.med-sovet.pro/jour/article/view/433 https://doaj.org/toc/2079-701X https://doaj.org/toc/2658-5790 |
| remote_bool |
true |
| ppnlink |
1760607460 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.21518/2079-701X-2015-17-96-103 |
| up_date |
2024-07-03T17:51:39.587Z |
| _version_ |
1803581233130635265 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ033457409</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505014245.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2015 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21518/2079-701X-2015-17-96-103</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ033457409</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7cfd404e358b4c21bbd3ad0daa4d73fe</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Leonova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacogenetics of proton pump inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Proton pump inhibitors (PPI) are currently the most effective class of antisecretory drugs widely used in the treatment of non-ulcer dyspepsia, reflux esophagitis and GERD, peptic ulcer disease and H. pilory infection, as well as NSAID-associated gastric lesions. Despite the common mechanism of action and pharmacological effects of this class of drugs, there is clinical inter-individual variability of their effect on acid production determined by pharmacokinetic and pharmacogenetic factors. As a result, the clinical efficacy of treatment of acid-base disorders and eradication of H. pilory is decreased.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ингибиторы протонной помпы</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">эрадикационная терапия</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">proton pump inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">eradication therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинский совет</subfield><subfield code="d">Remedium Group LLC, 2019</subfield><subfield code="g">(2015), 17, Seite 96-103</subfield><subfield code="w">(DE-627)1760607460</subfield><subfield code="x">26585790</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2015</subfield><subfield code="g">number:17</subfield><subfield code="g">pages:96-103</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21518/2079-701X-2015-17-96-103</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7cfd404e358b4c21bbd3ad0daa4d73fe</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.med-sovet.pro/jour/article/view/433</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-701X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5790</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2015</subfield><subfield code="e">17</subfield><subfield code="h">96-103</subfield></datafield></record></collection>
|
| score |
7.401143 |